Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | BCL10 |
| Gene Name: | BCL10 |
| Protein Full Name: | B-cell lymphoma/leukemia 10 |
| Alias: | B-cell CLL/lymphoma 10; BCL10; CARD containing molecule enhancing NF-kB; CARD-containing apoptotic signaling protein; CARD-containing molecule enhancing NF-kappa-B; CARD-containing proapoptotic protein; CARD-like apoptotic protein; CARMEN; Caspase-recruiting domain-containing protein; CCARMEN; C-E10; CED-3/ICH-1 prodomain homologous E10-like regulator; Cellular homolog of vCARMEN; Cellular-E10; CIPER; CLAP; HCLAP; Mammalian CARD-containing adapter molecule E10; ME10 |
| Mass (Da): | 26252 |
| Number AA: | 233 |
| UniProt ID: | O95999 |
| Locus ID: | 8915 |
| COSMIC ID: | BCL10 |
| Gene location on chromosome: | 1p22.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20382 |
| Percent of cancer specimens with mutations: | 0.26 |
| Normal role description: | Pro-apoptotic protein. Involves interacting with other apoptotic regulators with CARD domains to induce apoptosis and activate NF-KB signalling. May synergize with MALT1 for NF-KB activation. Signalling induces apoptosis. Dysregulation is involved in cancer progression and development. |
| Commentary on involvement of protein in cancer: | Sanger had no reports of anything above 4% |